Buradasınız

Anasayfa » Content

Safra taşı olan olgularda lipid profilleri

Lipid profiles of patients with gallstones

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2012

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Objective: Gall stone disease is an attractive subject for investiga¬tors due to its frequency, burden on health system and uncertainty of etiology. In this study, we studied lipid parameters, one of the probable causes of gallstones, and its relation with stone size and number. Methods: We evaluated lipid levels, body mass indexes and their correlation with the size and number of gallstones in patients attending to the internal medicine and general surgery clinics in Dr. Lütfi Kırdar Kartal Education and Training Hospital. A control group with similar features was also recruited. The lipid levels of the two groups were compared. For statistical evaluation, data was analyzed using SPSS 16.0 programme. Chi square and stu¬dent t tests were used for analyses, p levels <0.05 were accepted as statistically significant. Results: The study and control group consisted of 84 and 78 patients, respectively. The mean ages of these groups were 52.6±13.07 years and 49.58±1.48 years respectively. There were no significant differences between body mass indexes and lipid parameters of the two groups (p>0.05). Conclusions: As a result, we could not determine any significant difference between two groups for any of the lipid parameters. Also there were no correlation between any lipid parameters, size or number of stones.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Toplumda sık görülen gastrointestinal rahatsızlıklardan biri olan safra taşları gerek sağlık sistemine maliyeti ve gerekse hala aydınlatılamamış etiyolojisi açısından araştırmacıların ilgisini çeken bir konudur. Bu çalışmamızda safra taşlarının muhtemel etiyoloji-lerinden biri olan lipid düzeyleri ile safra taşı oluşumu, boyutu ve çoğul veya tekil olması arasındaki ilişki incelenmiştir. Yöntem: Bu amaçla Dr. Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi Dâhiliye ve Cerrahi Kliniklerine başvuran, safra taşı olan bireylerde lipid düzeyleri, vücut kitle indeksi ölçümleri ve safra taşlarının boyutları incelenmiştir. Benzer özellikteki bir kontrol grubu oluşturarak bu parametrelerin karşılaştırılması yapılmıştır. istatistiksel analiz için SPSS 16.0 programı kullanılmış, analizlerde ki kare ve t test kullanılmıştır. p değeri <0.05 olan değerler anlamlı olarak kabul edilmiştir. Bulgular: Çalışma grubu 84 ve kontrol grubu 78 kişiden oluşmaktaydı. Bu grupların ortalama yaşları sırasıyla 52.6±13.07 ve 49.58± 1.48 yıl idi. Gruplar arasında vücut kitle indeksi ve lipid parametre¬leri açısından istatistiksel olarak anlamlı farklılık bulunmamaktaydı (p>0.05). Sonuç: Çalışma sonucunda herhangi bir lipid parametresi açısından iki grup arasında anlamlı bir farklılık bulunamadı. Çalışma grubundaki lipid parametreleri ile çoklu taş oluşumu veya taş boyutu ile ilişki gösterilememiştir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_16_pp_123-126.pdf
  • 3
123-126
  • Turkish

REFERENCES

References: 

1. Aerts R, Penninckz F. The burden of gallstone disease in Europe. Aliment Pharamacol Ther 2003;18:49-53.
2. American Gastroenterological Association. The burden of gastrointestinal diseases. Bethesda, MD: The American Gastroenterological Association;
2001.
3. Sampliner RE, Bennett PH, Comess LJ, Rose FA, Burch TA. Gallbladder disease in Pima Indians: demonstration of high prevalence and early onset by cholecystography. N Engl J Med 1970;283:1358-64.
4. Carel T. Serum lipids and gallstones: a case-control study. Gastroenterology
1990:99;843-9.
5. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO). The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. Hepatology 1988;8:907-13.
6. Diehl AK. Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 1991;20:1-19.
7. Sandler RS, Everhart JE, Donowitz M, ve ark. The burden of selected digestive diseases in the US. Gastroenterology 2002;122:1500-11.
8. Shaheen JN, Hansen AR, Morgan DR, et al. The burden of gastrointesti¬nal and liver diseases. Am J Gastroenterol 2006;101:2128-38.
9.
Beyle
r AR, Uzunalimoğlu Ö, Gören A ve ark. Türkiye'de normal popü-lasyonda safra taşı sıklığı. The Turkish Journal of Gastroenterology 1993;4:
434-7
10. Angel A, Roncari DAK. Medical complication of obesity. Canad J MedSci
1978;119:1408-11.
11. Misciagna
G
, Guerra V, Di Leo A, Correale M, Trevisan M. Insulin and gall stones: a population case control study in southern Italy. Gut 2000;
47:144-7
12. Jorgensen T. Gall stones in a Danish population: fertility period, preg¬nancies, and exogenous female sex hormones. Gut 1988;29:433-9
13. Onodera H, Chida N, Abe M. Ultrasonic mass survey for liver, biliary tract and pancreatic diseases: a detection of gallbladder diseases. J Gastroent Mass
Survey1987;74:41-7.
14. Tanno N.,Koizumi M, Goto M. The relationship between cholelithiasis and diabetes mellitus :discussion of age, obesity,hiperlipidemia and neu¬ropathy. Tohoku J Exp Med1988;154:11-20.
15. Bartoli E, Capron JP. Epidemiology and natural history of cholelithiasis.
Rev Prat 2000;50:2112-6.
16. Kajiyama G, Horichui I, Yamada K, Kubota S. Levels of serum and bil¬iary lipids and their composition in patient with purecholesterol and mixed gallstones. Hiroshima J Med Sci 1982;31:11-9.
17. Liew PL, Wang W, Lee YC, Huang MT, Lin YC, Lee WJ Gallbladder disease among obese patients in Taiwan. Obes Surg2007;17:383-90.
18. Chen C, Huang H,Yang JC, ve ark. Prevalence and risk factors of gall¬stone disease in an adult population of Taiwan: an epidemiological survey.
J Gastroenterol Hepatol2006;21:1737-43.
19. Nervi F, Miquel FJ, Alverez M, ve ark. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006; 45:299-305
20. Scragg RKT, Calvert GD, Oliver RJ. Plasma lipids and insulin in gall stone disease: a case control study. B Med J1984;289:521-5.

Thank you for copying data from http://www.arastirmax.com